Vernakalant is a newly developed antiarrhythmic drug against atrial fibrillation (AF). However, its electrophysiological actions on human myocardium are unknown.
Introduction
The high prevalence of atrial fibrillation (AF) in the ageing western population has fuelled the search for new therapeutic interventions. Conventional antiarrhythmic drugs are burdened with low efficacy and serious cardiac and extracardiac side effects. For instance, Na + channel blockers with slow dissociation kinetics possess a clear propensity to provoke arrhythmias, in particular in patients with ischaemic heart disease. 1 Proarrhythmic effects are also known for K + channel blockers which can excessively prolong ventricular action potential duration (APD) leading to early afterdepolarizations that give rise to torsade-de-pointes arrhythmias.
2 Vernakalant (RSD1235) is a novel 'atrial-selective' antifibrillatory drug. It was developed as a multiple ion channel blocker and targets Na + channels (Nav1.5), various K + channels, and native K + currents with IC 50 values in the micromolar concentration range (Kv1.5, 13 mM; Kv4.2, 38 mM; Kv4.3, 30 mM; hERG, 21 mM; I K,ACh , 10 mM; I K1 . 1 mM). 3 Atrial selectivity refers to suppression of abnormal excitatory processes in the atria without proarrhythmic effects in the ventricles. Block of Na + channels is a generally accepted † E.W. and T.C. contributed equally to this work. ‡ Present address: Department of Experimental Pharmacology and Toxicology, University Clinics Hamburg-Eppendorf, Hamburg, Germany. § M.K. and U.R. share senior authorship.
antiarrhythmic mechanism (class I action according to 4 ) that was recently recognized to exhibit atrial selectivity when drug unbinding from the channels is potential dependent and rapid. 5 Potential dependency implies that drug affinity is higher at less negative membrane potential so that more drug will be bound and dissociation from the Na + channels will be slower than at more negative potential. Since resting membrane potential (RMP) in atrium is less negative than in ventricle, more drug will remain bound to and block Na + channels in atria than in ventricle, thereby exhibiting the atrial selectivity of Na + channel block. Atrial-selective drug effects are also conferred by I Kur blockade, since Kv1.5 channels are predominantly expressed in the human atria 6 and I Kur current is undetectable in the human ventricle. 7 Increased inward rectifying K + current can stabilize rotors. 8 However, only acetylcholine-activated current I K,ACh has been suggested to represent AF-specific drug targets, 9 although both constitutively active I K,ACh and Kir2.1 channel upregulation are hallmarks of the remodelled atria. 10 Block of I K1 is expected to be proarrhythmic because of its importance in the ventricles. As a result of its ion channel profile, vernakalant was shown to be atrial selective in humans.
11
Vernakalant has performed favourably in preclinical models of AF (see 12 for review). Several recent clinical studies demonstrated that vernakalant effectively and safely converts AF into sinus rhythm (SR). 13 -15 The AVRO trial, for instance, compared intravenous application of vernakalant vs. amiodarone for conversion of recent onset AF. Ninety minutes after initiation of therapy 51.7% of the patients had been successfully converted in the vernakalant group vs. 5.2% in the amiodarone group. 13 These results were instrumental for 18 -20 Here we have studied the effects of vernakalant in human atrial cardiomyocytes and trabeculae both from patients in SR and chronic AF. In addition to comparing the effects of vernakalant and accepted I Kur blockers on the shape of the atrial APs, we have also directly measured vernakalant's action on I Na , I to /I Kur , and I K,ACh in isolated human atrial cardiomyocytes. The aim of our study was to elucidate the putative mechanism of antiarrhythmic action by this novel drug in human tissue. Some of the data have been published previously in preliminary form. 21 2. Materials and methods
Human tissue samples and patients' characteristics
All work with human samples conforms to the Declaration of Helsinki. The study was approved by the ethics committee of Dresden University of Technology (No. EK790799). Each patient gave written, informed consent. Right atrial appendages were obtained from patients with SR and with long lasting AF (.6 months). The two groups differed significantly in age, in incidence of coronary artery disease (CAD), in CAD plus valvular disease, as well as in treatment with digitalis and lipid lowering drugs. For patients characteristics see Table 1 .
Electrophysiological recordings
APs were recorded with standard intracellular microelectrodes in atrial trabeculae. 19 Bath solution contained (in mM): NaCl 127, KCl 4.5, 20 ), and maximum upstroke velocity (dV/dt max ). The effective refractory period (ERP) was determined by applying an extra stimulus (2 × threshold voltage) at increasingly smaller intervals every 10th regular stimulus until failure of initiating an extra AP. APs were analysed offline by using the LabChart w software (ADInstruments, Spechbach, Germany). Human myocytes were isolated enzymatically from atrial appendages and the conventional voltage-clamp technique in the ruptured patch configuration was used to measure ion currents (I to , I Kur , I K,ACh , I K1 , and I Ca,L ) as previously described. 22 The compositions of superfusion and pipette solutions used for measurements of ion currents are given in Supplementary material online, 
Chemicals and drugs
Vernakalant was provided by Merck Research Laboratories. Tertiapin-Q was a gift from Xention (Cambridge, UK). All other compounds were purchased from Sigma (Steinheim, Germany).
Data analysis and statistics
For determining IC 50 values, sigmoidal functions were fitted to the mean data points of concentration response curves using GraphPad Prism (GraphPad Software Inc., San Diego, USA). Differences between continuous data were compared by paired (AP parameters) or unpaired Student's t-test (with Welch's correction if indicated) or one-way ANOVA. P , 0.05 was considered statistically significant.
Results

Effects of vernakalant on human right atrial action potentials
Based on the previously reported IC 50 values for ion channels expressed in human embryonic kidney cells 3 and on the therapeutic plasma concentration range measured in patients, 23 the effects of vernakalant on human atrial APs were studied at 10 and 30 mM (Figure 1) . At a frequency of 1 Hz, AP parameters of pre-drug control significantly differed in preparations from patients in SR and AF yielding the typical spike and dome and triangular shape in SR and AF, respectively. 19 In SR preparations, RMP was not significantly less negative compared with AF preparations, APA was smaller, plateau potential was more negative, APD 20 was shorter, and APD 90 was longer than in AF (see Supplementary material online, Tables S1 and S2). Moreover, SR and AF preparations exhibited distinctly different responses to vernakalant. In SR trabeculae, the most prominent effects of vernakalant (30 mM) were a significant slowing of early repolarization causing a widening of the spike, with some depression of the plateau phase, but little effect on final repolarization (APD 90 ), a rate-dependent reduction of the maximum upstroke velocity dV/dt max and APA. In AF, the prolonging effects of vernakalant on early and late repolarization phase (APD 20 and APD 90 , respectively) were variable in size, but nevertheless statistically significant for vernakalant (10 mM) at 0.5, 1, and 3 Hz (see Supplementary material online, Table S2 ). The ERP was significantly lengthened, and there was a trend for a larger increase in ERP than in APD 90 , although this did not reach the level of statistical significance. In SR trabeculae paced at 3 Hz, 30 mM vernakalant prolonged APD 90 by 29.6 + 19.4 ms, whereas mean ERP increased by 60.4 + 13.8 ms. In AF trabeculae, APD 90 and ERP were prolonged by 25.1 + 11.7 and 45.0 + 9.6 ms, respectively (for a complete list of all AP parameters for pre-drug control, 10 and 30 mM vernakalant at stimulation rates of 0.5, 1, and 3 Hz in comparison with time-matched controls (TMCs), see Supplementary material online, Table S1 for SR and Supplementary material online, Table S2 for AF). The frequency dependence of vernakalant's effect on dV/dt max was studied with the following experiment. After equilibration, but under pre-drug control conditions, frequency was increased in small steps for about 1 min ( Figure 1B ) until the preparations failed to respond to excitation (i.e. at 5 and 6 Hz in the SR and AF preparations, respectively). Upon return to 1 Hz, excitability recovered completely within 5 min. The muscles were then exposed to the first concentration of vernakalant (10 mM) for 20 min before the next series of increasing stimulation rates was started until excitation failed again. Then stimulation rate was returned back to 1 Hz, followed by addition of 30 mM vernakalant and renewed increase in stimulation rate. With 30 mM of vernakalant, excitation failed at even lower rates than with 10 mM. Moreover, suppression of dV/dt max with a given drug concentration was larger at higher stimulation rates, suggesting strong frequency dependence of drug effect. Figure 1C compares dV/dt max depression by 10 and 30 mM vernakalant expressed in percent of the pre-drug control values at the same frequency. Both in SR and AF preparations, vernakalant depressed maximum upstroke velocity to a larger extent at higher stimulation rates. This graph also allows a rough estimate of the frequency dependence of the IC 50 value for vernakalant: at 3 Hz, 50% of block was achieved with a concentration between 10 and 30 mM, whereas at 4 Hz and higher frequencies, less than 10 mM was sufficient for half-maximum block.
The shape of the cardiac AP is determined by current flow through various different ion channels. Therefore, we also performed voltage clamp experiments to establish the profile of vernakalant's action on ion channels in native human right atrial cardiomyocytes.
Effects of vernakalant on I Na
Sodium currents were studied with reduced extracellular Na + concentration (5 mM) in order to avoid loss of voltage control due to the huge initial current surge at physiological Na + concentrations.
Peak Na + current amplitudes normalized to cell capacitance were significantly lower ( 20%) in cardiomyocytes from patients in AF than from SR patients ( Figure 2 ). Vernakalant produced a concentrationdependent block of peak I Na amplitude. Fitting sigmoidal functions to the data points and assuming complete block of I Na by high concentrations of vernakalant ( Figure 2B ) yielded IC 50 values of 95 mM in SR and 84 mM in AF cells at a stimulation rate of 0.5 Hz. The currentvoltage (IV) curves ( Figure 2C and D) illustrate the potential dependence of block. The reversal potential for I Na of +15 mV was very close to the calculated liquid-junction potential of +11.4 mV. We were not able to investigate vernakalant's effect on late Na + current (I Na,late ) because we could not detect any I Na,late in SR or AF cells. 24 
Effects of vernakalant on I to /I Kur
In SR cells, K + currents activated with 500 ms long clamp steps from a holding potential of -60 mV to a test potential of +50 mV, consisted of a large peak transient component (I peak ) and a steady-state component (I late ). I peak was markedly smaller in AF than in SR, consistent with down regulation of Kv4.3 channels (conducting transient outward current I to ) in AF ( Figure 3A) . 22 Increasing concentrations of vernakalant (1-100 mM) slightly reduced I peak and I late in both groups of cells; however, similar changes also occurred in TMC experiments ('run-down') ( Figure 3B and C ). Because of the discrepancy between this finding and the vernakalant-induced prolongation in APD during the early phase of repolarization ('widening of spike'), we analysed the drug's effect during the initial 50 ms of a clamp step to +50 mV by calculating the area under the current-time curve (AUC) ( Figure 4A and B). The AUC remained constant in TMCs. In SR and AF cells, vernakalant accelerated the apparent rate of inactivation of the initial rapidly declining current component, producing a significant, concentration-dependent reduction in outward charge transfer during the early phase of the clamp step both in SR and AF ( Figure 4C and D) . The IC 50 values obtained by curve fitting to cumulative concentration -response curves for AUC were 19 and 12 mM for SR and AF, respectively.
Effects of vernakalant on I Kr
In human enzymatically dissociated cardiomyocytes, we have never been able to detect any I Kr , although the selective I Kr blocker E-4031 25 prolongs APD in human papillary muscle. 26 Therefore, direct effects of vernakalant on I Kr in native human atrial myocytes could not be tested. However, in atrial multicellular trabeculae, E-4031 significantly prolonged APD ( Figure 5 ) with EC 50 values of 181 and 201 nM in SR and AF preparations, respectively (n ¼ 7 in each group) ( Figure 5C and D) . Vernakalant, however, was ineffective in SR and slightly increased APD 90 in AF, as shown in Figure 5C and D.
3. Therefore, we have investigated whether vernakalant affects this current (see Supplementary material online, Figure S1 ). Under our experimental conditions, vernakalant reduced I Ca,L in a concentrationdependent manner with an IC 50 value of 84 mM in SR cells. With incremental frequency increases of the test steps between 0.5 and 6 Hz, vernakalant exhibited a stronger inhibitory effect on I Ca,L at higher frequencies, both in SR and AF (see Supplementary material online, Figure S1D and E). It should be noted, however, that also in the absence of drug, I Ca,L declined with increasing frequency, probably due to incomplete recovery from inactivation during shorter intervals. With 100 mM vernakalant, suppression of I Ca,L was limited to about 50%.
Effects of vernakalant on I K1 and I K,ACh
Inward rectifier K + current was measured during a 1000 ms ramp pulse from 2100 to +40 mV (pulse frequency 0.2 Hz) and current amplitude was analysed in the inward branch at 2100 mV. 28 I K,ACh was activated two times in succession by stimulating muscarinic receptors with carbachol (2 mM) for 2 min, followed by a 4 min wash-out period and renewed exposure (S1 and S2, respectively). Vernakalant (30 mM) was added 2 min prior to S2. Diary plots of basal current and I K,ACh are shown in Figure 6A . During exposure to carbachol (CCh), current amplitude at 2100 mV rapidly increased, and slowly decreased again due to desensitization. Moreover, S2 was always smaller, i.e. 0.8 of S1 due to incomplete recovery from desensitization. 28 Vernakalant (30 mM) significantly depressed I K,ACh in SR cells ( Figure 6B ). Effects of vernakalant on AF cells could not be estimated because of non-uniform effects of carbachol in AF cells. Using the selective I K,ACh channel blocker tertiapin, we have shown previously that I K,ACh becomes constitutively active in chronic AF because basal current is significantly reduced with tertiapin only in AF but not in SR, 10 and a similar trend is observed in the present experiments ( Figure 6C and D) . Vernakalant (30 mM), however, significantly reduced basal current in SR by 15.5 + 3.8% (from 8.2 + 1.0 to 7.2 + 1.0 pA/pF). In AF, basal current was reduced by 7.6 + 2.7% (from 16.9 + 2.9 to 15.5 + 2.6 pA/pF; Figure 6E and F ); however, this difference did not reach the level of statistical significance. In contrast, tertiapin had no effect on basal current in SR, indicating lack of constitutively active I K,ACh , but significantly reduced basal current in AF-as expected from constitutively active I K,ACh in this arrhythmia. Thus vernakalant has a small blocking effect on I K1 in SR.
Discussion
Vernakalant's electrophysiological and pharmacological properties have mainly been demonstrated in expression systems 3 or animal models of AF. 12 The major findings of our present study in human atrial tissue are that vernakalant prolonged early repolarization without elevating the plateau phase of the AP like other I to /I Kur blockers but reduced APA and maximum upstroke velocity dV/dt max in a rate-dependent manner. This suggests that Na + channel block dominates over I Kur block with respect to AP changes in isolated trabeculae.
Effects on action potentials
Typical I to /I Kur blockers, such as 4-aminopyridine 19, 29 or AVE0118, 22 elevate the plateau phase of human atrial APs and produce a significant positive inotropic effect. 19, 30, 31 Vernakalant also elevates the plateau and prolongs APD in cardiomyocytes from rat ventricle 3 which-unlike human ventricle-expresses functional Kv1.5 channels. 32 Similarly, vernakalant elevates the plateau in dog left atrium, consistent with I Kur /I to inhibition. 16 In contrast, vernakalant did not elevate the AP plateau or enhance force of contraction in human atrial trabeculae (unpublished result). This is unlike other I Kur blocking Effects of vernakalant in human atrial tissue drugs that elevate AP plateau and produce a robust positive inotropic response. These results suggest that I Kur block by vernakalant was not sufficient to elevate AP plateau in human atrial AP from SR patients. The reason for this finding is not entirely clear. Enzymatic destruction of targeted channels can be excluded because APs were recorded in intact trabeculae. Moreover, a recent report of the rate-dependent effects of vernakalant in dog left atrial preparations showed that sodium channel block was the major contributor. 33 The significant effect of vernakalant on outward current during the initial tens of ms of a clamp step (AUC in Figure 4 ) explains the 'widening of the spike' of the AP in SR, whereas in AF this may even produce the increase in APD 20 consistent with further inhibition of already downregulated early repolarizing current (i.e. I Kur and I to ). Vernakalant concentration-dependently attenuated APA and reduced dV/dt max . These findings support Na + channel blocking effect of vernakalant, since dV/dt max reflects availability of Na + channels. Vernakalant significantly prolonged ERP, i.e. at 3 Hz by 60 ms in SR and by 45 ms in AF with 30 mM. These increases compare well with previously reported in vivo measurements after intravenous drug application, where ERP was prolonged by 31 ms at a cycle length of 600 ms. 11 There was a trend for larger prolongation in ERP than in APD 90 , although not reaching the level of statistical significance. Nevertheless, this is in line with post-repolarization refractoriness due to Na + channel block.
Moreover, dV/dt max was reduced by vernakalant in a strongly frequency-dependent manner with less than 10 mM required for half-maximum block at stimulation rates higher than 3 Hz. Since reduction of dV/dt max impairs impulse conduction, this highly frequencydependent effect of vernakalant most likely explains the good clinical efficacy of the drug in acute conversion of recent onset AF into SR. 13 -15 Nevertheless, we have also analysed the direct effects of vernakalant on human atrial I Na .
I Na and I Na,late
In AF, peak atrial I Na was moderately smaller than in SR, confirming published data. 34, 35 Vernakalant blocked I Na with similar potency in SR and AF cells, the IC 50 values were 95 and 84 mM, respectively, at pulse frequency 0.5 Hz, and correspond well to results in rat ventricular cells taking into account the strong potential and frequency dependence of I Na block by vernakalant. 3, 12 The authors reported IC 50 values of 43 and 9 mM for pacing rates of 1 and 20 Hz, respectively, at a holding potential of 280 mV, and 107 mM for 1 Hz at 2120 mV. Vernakalant was reported to suppress I Na,late measured with Nav1.5 expressed in HEK cells; 36 however, with a similar protocol we failed to detect I Na-late in human atrial SR and AF preparations. 24 
I to /I Kur
In human atrial cardiomyocytes, the transient outward current I to and the ultra-rapidly activating K + current I Kur exhibited substantial temporal overlap at physiological temperature. As a crude distinction, peak and late current were considered to represent I to and I Kur , respectively. In comparison with TMC, vernakalant did not significantly reduce either peak or late outward current of human atrial cardiomyocytes at physiological temperature, but attenuated early charge transfer (AUC) by apparent acceleration of inactivation of the initial components of transient outward currents. Since Kv1.5 channels expressed in a mouse fibroblast cell line inactivate rapidly at physiological temperature, 22 the apparent acceleration of current inactivation observed during the initial 50 ms of the clamp step in native cardiomyocytes could be due to block of I to or I Kur or both. The IC 50 values for the effects on AUC (19 and 12 mM) were within the range reported for expressed Kv1.5 (13 mM) and Kv4.3 (30 mM) 3 and hence do not allow to distinguish between I to and I Kur . Moreover, modelling of vernakalant binding to Kv1.5 channels suggests a high affinity to activated open channels. 37 In any case, enhanced decline of early outward current can explain the 'widening of spike' and increased APD 20 as observed in AP recordings from SR and AF patients.
The small size of vernakalant-induced block of I Kur in native atrial cardiomyocytes was surprising given the efficacious I Kur block reported in expression systems. 3 In native atrial cells, vernakalant neither affected I peak nor I late . Only when early outward current was analysed by measuring the AUC during the initial 50 ms could we detect any significant block of outward current. Therefore, it is not surprising that vernakalant did not elevate AP plateau like other I to /I Kur blockers, as for instance AVE0118. In our hands, we could not detect I Kr in human atrial cardiomyocytes which may be related to the use of the 'chunk' rather than 'perfusion' isolation method 38 or to destruction of hERG channels by serine proteases used for enzymatic dissociation. 33 Nevertheless, in multicellular preparation, the I Kr blocker E-4031 prolonged APD with similar EC 50 values in SR and AF trabeculae suggesting the presence of functional hERG channels in intact atrial tissue strips. Interestingly, human tissue remodelled by chronic AF maintained its sensitivity to the class III E-4031, whereas in a goat model of short-term AF (2 days), the class III drug sotalol lost its efficacy to prolong APD. 39 The discrepancy is probably due to differences in models. Vernakalant blocks hERG channels expressed in HEK cells with an IC 50 of 21 mM. Equivalent concentrations of vernakalant (10-30 mM) did not at all imitate the strong delay in final repolarization observed with E-4031, thus providing circumstantial evidence for lack of a major contribution of I Kr block by vernakalant to the observed AP changes. However, vernakalant also blocked L-type Ca 2+ channels with an IC 50 of 42 mM, indicating that human atrial I Ca,L may be more sensitive to block than its counterpart in rat ventricle. 3 Although block of I Ca,L is expected to be small at clinically relevant concentrations, it could nevertheless increase repolarization reserve and hence attenuate APD prolongation by hERG channel block. 27 Similarly, block of putative late sodium current could counteract the APD-prolonging effect of potassium channel block. However, unlike recently reported 35 we have not detected any I Na,late in human atrial cardiomyocytes, neither from SR nor AF patients. 24 
I K,ACh , I K1
In SR atrial cardiomyocytes, vernakalant attenuated activation of I K,ACh by carbachol. Similar experiments were not carried out in AF cells because (carbachol-sensitive) I K,ACh is down-regulated in AF. 28 Only AF cells exhibited a tertiapin-sensitive component of basal inward rectifier which was interpreted as due to constitutively active I K,ACh , 10, 40 although the current amplitude was smaller than previously reported. The reason for this discrepancy with our published data remains unclear.
Vernakalant also impaired basal current in SR cells indicating some effect on inward rectifier I K1 . Since RMP was not significantly changed (Supplementary material online, Table S1 ), this small decrease in basal current does not have any functional consequences, but suggests stronger effect on human atrial I K1 than initially reported in guinea pig ventricular myocytes (IC 50 . 1 mM). 3 In AF cells, decrease of basal current by vernakalant did not reach statistical significance. In any case, attenuation of basal current could be attributed either to block of I K1 , constitutively active I K,ACh , or both. Nevertheless, some effects on additional background currents can presently not be ruled out. Single channel measurements are required to distinguish between these possibilities.
Future perspective
In native cardiomyocytes, it is often difficult to separate drug actions on multiple ion channels because of overlap in potential range of current activation and inactivation or lack of highly selective blockers.
As a future perspective, we will try to obtain support for our interpretation from an appropriate computational model which can reproduce the AP data.
Clinical implications
Vernakalant is intravenously applied for conversion of recent-onset AF and several clinical trials have demonstrated that the drug is effective and safe. 13 -15 Despite profound electrical remodelling in chronic AF, 41 we could not detect any differences in efficacy of block of ion channels by vernakalant between SR and AF at the cellular level. Interestingly, vernakalant's ion channel profile resulted in larger effects on APD in AF where electrical remodelling occurred, than in SR.
Provided that atrial electrophysiological properties in recent-onset AF still resemble those of SR, the antiarrhythmic effect of vernakalant is most likely due to rate-dependent block of Na + channels rather than I Kur block. In addition, the rapid rates of excitation in AF will enhance the atrial-selective antiarrhythmic potency of vernakalant. At physiological stimulation rates, open channel block of early transient outward currents and I K,ACh could also contribute.
Study limitations
RMP was always larger (more negative) in preparations from AF patients compared with SR patients. Although higher expression of inward rectifier K + channels in AF may serve as a satisfactory explanation, 28 technical reasons cannot be ruled out. Stable impalement of the microelectrode is more easily obtained in AF preparations due to less tissue motion because of AF-induced contractile dysfunction. 42 
Supplementary material
Supplementary material is available at Cardiovascular Research online. Effects of vernakalant in human atrial tissue
